Keyphrases
Magnetic Resonance Imaging
100%
Pathological Response
100%
Neoadjuvant Chemotherapy
100%
Breast Magnetic Resonance Imaging
100%
Negative Predictive Value
60%
Positive Predictive Value
40%
Sensitivity Specificity
40%
HER2+
40%
Invasive Breast Cancer
30%
Pathological Complete Response
30%
Tumor Characteristics
20%
Molecular Subtypes
20%
Post-treatment Imaging
20%
Image Performance
20%
Tumor
10%
Molecular Subset
10%
Multivariate Analysis
10%
Tumor Subtype
10%
Patient Characteristics
10%
Estrogen Receptor Status
10%
Breast Cancer Subtypes
10%
Paclitaxel
10%
Patient Treatment
10%
Response to Neoadjuvant Chemotherapy
10%
Neoadjuvant Therapy
10%
Image Accuracy
10%
Trastuzumab
10%
Molecular Characteristics
10%
Patient Tumor
10%
Molecular Profile
10%
Conflicting Results
10%
Distinct Subtypes
10%
Progesterone Receptor Expression
10%
Treatment Characteristics
10%
Background Prior
10%
Radiological Response
10%
Triple Negative
10%
Doxorubicin-cyclophosphamide
10%
Neoadjuvant Systemic Therapy
10%
HER2 Status
10%
Breast Magnetic Resonance Image
10%
Medicine and Dentistry
Neoplasm
100%
Neoadjuvant Chemotherapy
100%
Magnetic Resonance Imaging of Breast
100%
Receptor
50%
Breast Cancer
50%
Magnetic Resonance Imaging
25%
Estrogen Receptor
25%
Progesterone Receptor
25%
Multivariate Analysis
25%
Neoadjuvant Therapy
25%
Systemic Therapy
25%
Trastuzumab
25%
Breast Cancer Molecular Subtype
25%
Cyclophosphamide Plus Doxorubicin Plus Taxane
25%
Diseases
25%
Nursing and Health Professions
Predictive Value
100%
Neoadjuvant Chemotherapy
100%
Nuclear Magnetic Resonance Imaging
100%
Neoplasm
40%
Breast Cancer
20%
Receptor
20%
Imaging
10%
Multivariate Analysis
10%
Neoadjuvant Therapy
10%
Estrogen Receptor
10%
Progesterone Receptor
10%
Systemic Therapy
10%
Trastuzumab
10%
Cyclophosphamide Plus Doxorubicin Plus Taxane
10%
Breast Cancer Molecular Subtype
10%
Diseases
10%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Chemotherapy
100%
Receptor
50%
Breast Cancer
50%
Progesterone Receptor
25%
Estrogen Receptor
25%
Trastuzumab
25%
Breast Cancer Molecular Subtype
25%
Cyclophosphamide Plus Doxorubicin Plus Taxane
25%
Diseases
25%
Biochemistry, Genetics and Molecular Biology
Magnetism
100%
Magnetic Resonance Imaging
100%
Progesterone Receptor
10%
Estrogen Receptor
10%
Multivariate Analysis
10%
Trastuzumab
10%
Cyclophosphamide
10%
Doxorubicin
10%
Immunology and Microbiology
Magnetic Resonance Imaging
100%
Magnetism
100%
Trastuzumab
10%
Cyclophosphamide Plus Doxorubicin Plus Taxane
10%